A STUDY ON SHORT-TERM IMPACT OF DAPAGLIFLOZIN ON DIASTOLIC CARDIAC PARAMETERS IN TYPE 2 DIABETES MELLITUS PATIENTS WITH NORMAL EJECTION FRACTION

Background and objectives: Type 2 Diabetes Mellitus (T2 DM) is a leading independent cardiovascular risk factor for developing both systolic and diastolic heart failure (HF). Sodium Glucose Co Transporter 2 (SGLT2) inhibitor Dapagliflozin has proven significant beneficial effect in reducing incidence of major adverse cardio-vascular events (MACE) and hospitalization due to heart failure (HHF) in patients with atherosclerotic cardio-vascular diseases (ASCVD) and established HF. To document the prognostic impact of SGLT2 inhibitor Dapagliflozin in left ventricular diastolic function in T2DM patients with normal ejection fraction is the purpose of our study for future strategic planning for treatment of heart failure. Methods:The study enrolled 100 participants diagnosed with T2DM and preserved ejection fraction. The inclusion criteria ensured that participants had evidence of diastolic dysfunction without acute decompensated heart failure. Echocardiographic evaluation was performed to assess diastolic parameters, including the E/e′ ratio, left atrial volume index (LAVI), and mitral E/A ratio. The participants were treated with Dapagliflozin for six months, and follow up echocardiographic assessments were conducted to evaluate changes in diastolic parameters. Statistical analysis included paired t-tests, chi-square tests, and p-values to compare pre- and post-treatment data.